The first patient has been dosed in a phase 1/2 clinical trial investigating 4D-150 for the treatment of wet age-related macular degeneration, according to a press release from 4D Molecular Therapeutics.
“4D-150 is a dual-transgene intravitreal gene therapy incorporating the R100 capsid, which we invented through our proprietary Therapeutic Vector Evolution platform,” David Kirn, MD, co-founder and CEO of 4DMT, said in the release.
The company anticipates enrolling 60 adults in the dose-escalation, randomized, controlled, masked expansion trial.
In the dose-escalation phase,